Literature DB >> 28298257

The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer.

Takaaki Ito1, Teiichi Sugiura2, Yukiyasu Okamura2, Yusuke Yamamoto2, Ryo Ashida2, Takeshi Aramaki3, Masahiro Endo3, Katsuhiko Uesaka2.   

Abstract

BACKGROUND: Liver metastases (LMs) are sometimes diagnosed intraoperatively, even when multidetector-row computed tomography (MDCT) reveals no LM in the staging of pancreatic cancer (PC). Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MR imaging) may have a role to play in the detection of LM.
METHODS: The present study included a total of 201 patients who underwent an EOB-MR imaging examination before undergoing surgical resection for pancreatic cancer that was determined to be radiologically-resectable by MDCT. Intrahepatic lesions that were considered suspected to be liver metastases following an EOB-MR imaging examination were defined as possible lesions (PLs). All PLs were evaluated by a pathological examination or through close follow-up examinations. The diagnostic ability of EOB-MR imaging was assessed. The predictive factors for liver metastasis were evaluated.
RESULTS: Thirty-seven PLs were noted in 17 patients: 31 PLs were true LMs, and six were benign lesions (3 hemangiomas and 3 abscesses). Nine LMs were newly detected during surgery and were not detected by preoperative EOB-MR imaging. The diagnostic ability of EOB-MR imaging was as follows: sensitivity, 77.5%; specificity, 94.7%; positive predictive value, 83.8%; negative predictive value, 92.3%; and accuracy, 90.2%. A multivariate analysis revealed that the presence of PL on EOB-MR imaging was the only independent risk factor for intraoperative liver metastasis (P < 0.001).
CONCLUSION: EOB-MR imaging was useful in detecting tiny liver metastases from pancreatic cancer in cases that were determined to be radiologically resectable by MDCT.
Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Liver metastasis; Magnetic resonance imaging; Pancreatic cancer

Mesh:

Substances:

Year:  2017        PMID: 28298257     DOI: 10.1016/j.pan.2017.03.001

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

1.  Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT.

Authors:  Sun Kyung Jeon; Jeong Min Lee; Ijin Joo; Dong Ho Lee; Su Joa Ahn; Hyunsik Woo; Myoung Seok Lee; Jin-Young Jang; Joon Koo Han
Journal:  Eur Radiol       Date:  2018-01-19       Impact factor: 5.315

2.  Convolutional neural network-automated hepatobiliary phase adequacy evaluation may optimize examination time.

Authors:  Guilherme Moura Cunha; Kyle A Hasenstab; Atsushi Higaki; Kang Wang; Timo Delgado; Ryan L Brunsing; Alexandra Schlein; Armin Schwartzman; Albert Hsiao; Claude B Sirlin; Katie J Fowler
Journal:  Eur J Radiol       Date:  2020-01-14       Impact factor: 3.528

3.  CT and MRI of pancreatic cancer: there is no rose without a thorn!

Authors:  N Kartalis
Journal:  Eur Radiol       Date:  2018-05-23       Impact factor: 5.315

4.  Can preoperative liver MRI with gadoxetic acid help reduce open-close laparotomies for curative intent pancreatic cancer surgery?

Authors:  Kartik S Jhaveri; Ali Babaei Jandaghi; Seng Thipphavong; Osvaldo Espin-Garcia; Anna Dodd; Shawn Hutchinson; Trevor W Reichman; Carol-Anne Moulton; Ian D McGilvary; Steven Gallinger
Journal:  Cancer Imaging       Date:  2021-06-30       Impact factor: 3.909

5.  Neoadjuvant chemotherapy followed by curative-intent surgery for perihilar cholangiocarcinoma based on its anatomical resectability classification and lymph node status.

Authors:  Naohisa Kuriyama; Masanobu Usui; Kazuaki Gyoten; Aoi Hayasaki; Takehiro Fujii; Yusuke Iizawa; Hiroyuki Kato; Yasuhiro Murata; Akihiro Tanemura; Masashi Kishiwada; Hiroyuki Sakurai; Shugo Mizuno; Shuji Isaji
Journal:  BMC Cancer       Date:  2020-05-11       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.